DK0822829T3 - Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser - Google Patents

Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser

Info

Publication number
DK0822829T3
DK0822829T3 DK97906022T DK97906022T DK0822829T3 DK 0822829 T3 DK0822829 T3 DK 0822829T3 DK 97906022 T DK97906022 T DK 97906022T DK 97906022 T DK97906022 T DK 97906022T DK 0822829 T3 DK0822829 T3 DK 0822829T3
Authority
DK
Denmark
Prior art keywords
gdnf
neurotrophic factor
treatment
vestibular
neurons
Prior art date
Application number
DK97906022T
Other languages
Danish (da)
English (en)
Inventor
Ella Magal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/606,176 external-priority patent/US5837681A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0822829T3 publication Critical patent/DK0822829T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK97906022T 1996-02-23 1997-02-14 Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser DK0822829T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/606,176 US5837681A (en) 1996-02-23 1996-02-23 Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US08/710,219 US5929041A (en) 1996-02-23 1996-09-13 Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
PCT/US1997/002677 WO1997030722A1 (en) 1996-02-23 1997-02-14 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders

Publications (1)

Publication Number Publication Date
DK0822829T3 true DK0822829T3 (da) 2002-04-02

Family

ID=27085161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97906022T DK0822829T3 (da) 1996-02-23 1997-02-14 Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser

Country Status (21)

Country Link
US (1) US5929041A (de)
EP (1) EP0822829B1 (de)
JP (1) JP4028598B2 (de)
KR (1) KR100271247B1 (de)
CN (1) CN1130221C (de)
AT (1) ATE211392T1 (de)
AU (1) AU691443B2 (de)
CA (1) CA2217565C (de)
CZ (1) CZ322797A3 (de)
DE (1) DE69709458T2 (de)
DK (1) DK0822829T3 (de)
EA (1) EA199700225A1 (de)
ES (1) ES2170938T3 (de)
HU (1) HU223999B1 (de)
IL (1) IL121790A (de)
MX (1) MX9707669A (de)
NO (1) NO974767L (de)
NZ (1) NZ328918A (de)
PT (1) PT822829E (de)
SK (1) SK138697A3 (de)
WO (1) WO1997030722A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
EP1304119A3 (de) * 1997-07-30 2004-01-21 Amgen Inc. Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7236888B2 (en) * 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
DE69936059T2 (de) 1998-09-25 2008-01-24 Cephalon, Inc. Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
US6838444B1 (en) * 1999-06-01 2005-01-04 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
CA2385929A1 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US6551575B1 (en) * 1999-12-02 2003-04-22 Neurosciences Research Foundation, Inc. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
AUPR148400A0 (en) 2000-11-14 2000-12-07 Cochlear Limited Apparatus for delivery of pharmaceuticals to the cochlea
US9089450B2 (en) * 2000-11-14 2015-07-28 Cochlear Limited Implantatable component having an accessible lumen and a drug release capsule for introduction into same
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
AUPS081502A0 (en) * 2002-02-28 2002-03-21 Cochlear Limited Connector for drug delivery system
US7390482B2 (en) 2002-10-02 2008-06-24 Anges Mg, Inc. Drug for auditory dysfunction
WO2004050056A1 (en) * 2002-11-29 2004-06-17 Cochlear Limited Cochlear implant drug delivery device
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8133215B2 (en) * 2007-08-13 2012-03-13 Cochlear Limited Independently-manufactured drug delivery module and corresponding receptacle in an implantable medical device
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
US8190271B2 (en) * 2007-08-29 2012-05-29 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8617097B2 (en) 2010-05-24 2013-12-31 Cochlear Limited Drug-delivery accessory for an implantable medical device
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US10265380B2 (en) 2014-03-05 2019-04-23 Amarantus Bioscience Holdings, Inc. Method of administering MANF for the protection of sensory cells
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CA3022915A1 (en) * 2016-05-03 2017-11-09 The Scripps Research Institute Trkb agonist antibodies for treating neurodegenerative disorders
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
EP3406259A1 (de) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophine zur verwendung bei der behandlung von hörverlust
CA3087574A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
CN112920998B (zh) * 2021-02-05 2022-06-14 复旦大学附属眼耳鼻喉科医院 一种成年鼠耳蜗体培养体系的建立方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
EP0802800B1 (de) * 1993-08-12 2002-06-12 Neurotech S.A. Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
JP4028598B2 (ja) 2007-12-26
EP0822829A1 (de) 1998-02-11
CZ322797A3 (cs) 1998-01-14
MX9707669A (es) 1997-11-29
CA2217565A1 (en) 1997-08-28
AU2277997A (en) 1997-09-10
HUP9901758A2 (hu) 1999-08-30
PT822829E (pt) 2002-06-28
HUP9901758A3 (en) 2001-10-29
SK138697A3 (en) 1998-02-04
EP0822829B1 (de) 2002-01-02
NO974767D0 (no) 1997-10-15
AU691443B2 (en) 1998-05-14
ES2170938T3 (es) 2002-08-16
HU223999B1 (hu) 2005-04-28
CN1130221C (zh) 2003-12-10
DE69709458D1 (de) 2002-02-07
EA199700225A1 (ru) 1998-04-30
KR100271247B1 (ko) 2000-11-01
ATE211392T1 (de) 2002-01-15
NO974767L (no) 1997-12-22
NZ328918A (en) 1999-08-30
IL121790A0 (en) 1998-02-22
CA2217565C (en) 2002-04-16
DE69709458T2 (de) 2002-08-29
WO1997030722A1 (en) 1997-08-28
CN1181704A (zh) 1998-05-13
KR19980703748A (ko) 1998-12-05
US5929041A (en) 1999-07-27
JPH11504351A (ja) 1999-04-20
IL121790A (en) 2002-08-14

Similar Documents

Publication Publication Date Title
DK0822829T3 (da) Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
DK0866719T3 (da) Fremgangsmåde til behandling af retina-gangliecellelæsion under anvendelse af gliacellelinjeafladt neurotrof faktor (GDNF)-
DK1574209T3 (da) Fremgangsmåde til behandling af ophthalmiske sygdomme
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
SI0725779T1 (de)
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
HK1040053A1 (en) Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ES2074276T3 (es) Metodo de tratamiento de la alopecia.
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
ATE263559T1 (de) Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
EP1304119A3 (de) Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein
DE69516602T2 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
NZ323207A (en) Hemoregulatory compounds
WO2001072955A3 (en) Regulation of human nedd1-related protein
TR200000916T2 (tr) İkameli piperidin türevleri.